A new rapid-acting injectable antibiotic for pigs - until now only available on the continent - has been launched in the UK by Schering-Plough Animal Health.
Introducing the product at a series of evening discussion meetings, Dr Luc Goossens, Director of Technical Services for Schering-Plough presented the background to Nuflor and identified its key advantages: "In the treatment of swine conditions Nuflor demonstrates almost 100% bio-availability and excellent levels of tissue penetration. It is absorbed rapidly and reaches active kill levels in under an hour. In clinical trials Nuflor has consistently out performed older antibiotics in the treatment of a wide range of diseases in swine," he said.
Developed as a broad-spectrum antibiotic, Nuflor Swine is highly effective in the treatment of a wide range of pig conditions including Mycoplasma hyopneumoniae, Pasteurella multocida, Streptococcus suis and Haemophilus parasuis. The florfenicol antibiotic, derived from the Chloramphenicol group, is seen as delivering considerable benefits over older available antibiotics, without the resistance and human safety issues seen with Chloramphenicol. Nuflor is designed specifically for animal use and is not used in human medicine.
Schering-Plough Animal Health Pig Brand Manager Sam Gayton commented: "Nuflor is a proven antibiotic in the control of bovine respiratory disease and we are delighted that the pig sector can now benefit from its treatment dividends too. Our feedback indicates that the pig veterinary community recognises the extensive research we have undertaken to bring this product to market. I believe that it will prove a highly valuable treatment for pig herds in the UK."
